Multi-matrix system mesalamine: to use or not to use.
Pramodini B Kale-Pradhan1, Rohan S Pradhan, Sheila M Wilhelm
1Wayne State University, St. John Hospital and Medical Center, Detroit, MI 48236, USA. pkale@wayne.edu.
The Annals of Pharmacotherapy
|January 10, 2008
Summary
Multi-Matrix System (MMX) mesalamine effectively treats mild-to-moderate ulcerative colitis (UC), inducing remission with improved adherence due to once-daily dosing. This oral formulation offers better patient acceptance than topical treatments.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Standard treatments for ulcerative colitis (UC) include aminosalicylates, but current mesalamine formulations present challenges in patient adherence due to complex dosing and high pill burden.
- The Multi-Matrix System (MMX) mesalamine offers a novel approach to delivering mesalamine for UC treatment.
Purpose of the Study:
- To evaluate the efficacy and role of Multi-Matrix System (MMX) mesalamine in managing mild-to-moderate ulcerative colitis (UC).
Main Methods:
- A comprehensive literature search was conducted using MEDLINE and bibliographic reviews, including English-language primary literature.
- Key search terms included ulcerative colitis, mesalamine, MMX, SPD476, and Lialda.
Main Results:
- MMX mesalamine demonstrated higher rates of clinical and endoscopic remission compared to placebo in patients with mild-to-moderate UC.
- Statistically significant remission rates were observed with MMX mesalamine at daily doses of 2.4 g and 4.8 g compared to placebo.
- MMX mesalamine was well-tolerated, with headache, flatulence, and abdominal pain as the most common adverse events.
Conclusions:
- Evidence supports MMX mesalamine (2.4-4.8 g daily) for inducing remission in mild-to-moderate UC.
- Advantages include once-daily dosing, reduced pill burden, and potentially improved patient acceptability over topical formulations.
- MMX mesalamine is a viable treatment option for UC, with costs comparable to other mesalamine formulations; further pharmacoeconomic studies are recommended.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:19Mesenchymal Stem Cells
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...